268 related articles for article (PubMed ID: 25323242)
21. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
23. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients].
Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ
Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499
[TBL] [Abstract][Full Text] [Related]
24. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
25. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
26. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
27. Nebuliser systems for drug delivery in cystic fibrosis.
Daniels T; Mills N; Whitaker P
Cochrane Database Syst Rev; 2013 Apr; (4):CD007639. PubMed ID: 23633344
[TBL] [Abstract][Full Text] [Related]
28. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
29. Inhaled antibiotics.
Tiddens H
Pediatr Pulmonol Suppl; 2004; 26():92-4. PubMed ID: 15029611
[No Abstract] [Full Text] [Related]
30. [Characterization by isotope method of the performance of the pneumatic nebulizer NL9 Atomizer in the production of colistin, tobramycin and amiloride aerosols].
Diot P; Le Pape A; Boissinot E; Lemarié E
Rev Mal Respir; 1994; 11(6):573-8. PubMed ID: 7831507
[TBL] [Abstract][Full Text] [Related]
31. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
[TBL] [Abstract][Full Text] [Related]
32. Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany.
Naehrig S; Schulte-Hubbert B; Hafkemeyer S; Hammermann J; Dumke M; Sieber S; ; Naehrlich L
Pulm Pharmacol Ther; 2023 Jun; 80():102214. PubMed ID: 37003541
[TBL] [Abstract][Full Text] [Related]
33. Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe.
Sloan CM; Sherrard LJ; Einarsson GG; Dupont LJ; Koningsbruggen-Rietschel SV; Simmonds NJ; Downey DG
J Cyst Fibros; 2024 May; 23(3):499-505. PubMed ID: 38360460
[TBL] [Abstract][Full Text] [Related]
34. [Pulmonary deposition of colistin aerosols in cystic fibrosis. Comparison of an ultrasonic nebulizer and a pneumatic nebulizer].
Gagnadoux F; Diot P; Marchand S; Thompson R; Dieckman K; Lemarié E; Varaigne F; Maurage C; Baulieu JL; Rolland JC
Rev Mal Respir; 1996; 13(1):55-60. PubMed ID: 8650418
[TBL] [Abstract][Full Text] [Related]
35. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Chuchalin A; Amelina E; Bianco F
Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs.
Kukut Hatipoglu M; Hickey AJ; Garcia-Contreras L
Int J Pharm; 2018 Oct; 549(1-2):306-316. PubMed ID: 30077761
[TBL] [Abstract][Full Text] [Related]
37. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
38. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation.
Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696
[TBL] [Abstract][Full Text] [Related]
39. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
40. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
